| Marnix A Verhofste, MD | |
|
411 Laurel St, Suite A250, Des Moines, IA 50314-3017 | |
| (515) 235-5000 | |
| (515) 288-6713 |
| Full Name | Marnix A Verhofste |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 38 Years |
| Location | 411 Laurel St, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821070657 | NPI | - | NPPES |
| 2166736 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 31865 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercyone Des Moines Medical Center | Des moines, IA | Hospital |
| Boone County Hospital | Boone, IA | Hospital |
| Mercyone Centerville Medical Center | Centerville, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Catholic Health Initiatives-iowa Corp | 5698683142 | 112 |
News Archive
Researchers have identified a set of criteria that, when combined with a measure of kidney function, could help identify patients who are likely to receive a survival benefit from a combined heart and kidney transplant, according to a report in the March issue of Archives of Surgery.
The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.
Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos' TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
› Verified 9 days ago
| Entity Name | Catholic Health Initiatives-iowa Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508964883 PECOS PAC ID: 5698683142 Enrollment ID: O20031118000163 |
News Archive
Researchers have identified a set of criteria that, when combined with a measure of kidney function, could help identify patients who are likely to receive a survival benefit from a combined heart and kidney transplant, according to a report in the March issue of Archives of Surgery.
The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.
Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos' TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
› Verified 9 days ago
| Entity Name | Broadlawns Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467447508 PECOS PAC ID: 3678466166 Enrollment ID: O20040206000913 |
News Archive
Researchers have identified a set of criteria that, when combined with a measure of kidney function, could help identify patients who are likely to receive a survival benefit from a combined heart and kidney transplant, according to a report in the March issue of Archives of Surgery.
The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.
Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos' TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marnix A Verhofste, MD 5880 University Ave, Suite 205, West Des Moines, IA 50266-8220 Ph: (515) 633-3835 | Marnix A Verhofste, MD 411 Laurel St, Suite A250, Des Moines, IA 50314-3017 Ph: (515) 235-5000 |
News Archive
Researchers have identified a set of criteria that, when combined with a measure of kidney function, could help identify patients who are likely to receive a survival benefit from a combined heart and kidney transplant, according to a report in the March issue of Archives of Surgery.
The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.
Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos' TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative' breast cancers. The partnership will continue for a further three years.
› Verified 9 days ago
Dr. Ganga Prabhakar, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 411 Laurel St, Suite 250, Des Moines, IA 50314 Phone: 515-235-5000 Fax: 515-288-6713 | |
David R Hockmuth, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 411 Laurel St, Suite A250, Des Moines, IA 50314 Phone: 515-235-5000 Fax: 515-288-6713 | |
Bart P Jenson, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1215 Pleasant St, Suite 414, Des Moines, IA 50309 Phone: 515-241-8033 Fax: 515-241-8036 | |
Mark Mankins, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1215 Pleasant St Ste 618, Des Moines, IA 50309 Phone: 515-875-9090 Fax: 515-875-9736 | |
Dr. Robert F Schneider, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1215 Pleasant St, Ste 618, Des Moines, IA 50309 Phone: 515-875-9090 Fax: 515-241-5041 | |
Dr. Kent C Thieman, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1215 Pleasant St, Ste 618, Des Moines, IA 50309 Phone: 515-875-9090 Fax: 515-241-5041 |